The CRT 2026 conference showcased a wave of fresh clinical data that could reshape how doctors treat heart disease. One highlight was the five‑year follow‑up of the SUGAR trial, which compared two drug‑coated stents—sirolimus‑eluting versus zotarolimus‑eluting—in patients with diabetes, showing promising long‑term safety. Another study, the Eclipse trial, examined whether orbital atherectomy (a specialized drill) works better than standard balloon angioplasty for severely calcified coronary arteries, with encouraging two‑year results. In the realm of structural heart disease, researchers presented seven‑year health‑status outcomes for patients with severe aortic stenosis who received either a transcatheter or surgical valve replacement, confirming that the less‑invasive transcatheter approach holds up well in low‑risk patients. A separate trial found that the diabetes drug tirzepatide can cut hidden clot formation and leaks around the new valve in obese patients. Long‑term data from the Evolut low‑risk trial and real‑world Medicare re‑intervention rates further support the durability of transcatheter valves. Other notable findings included a head‑to‑head comparison of clopidogrel versus aspirin after stent placement, 12‑month outcomes for the SELUTION DeNovo device, and early‑stage trials testing IL‑6 blockers and low‑dose dobutamine in heart‑attack patients. Together, these studies point to safer, more effective options for millions battling coronary and valve disease.
Read more